Genedata

Join Novartis, OmniAb, Merck & Co., and Genedata to see how leading biopharma organizations are applying a new approach to advanced analytics for automating workflows, connecting data, and supporting scientific decision-making across discovery, development, and downstream processing.

Genedata Screener helps R&D teams move from raw experimental data to confident decisions faster — with automation that scales as science and organisations evolve. Screener provides a single platform for: • Low to high complexity assays, at any throughput • Small molecule, biologics, and advanced modality research • Automated, reproducible analysis across teams, labs, and sites • Cell based and phenotypic, biochemical and molecular, biophysical, signal transduction assays Designed to connect data, workflows, and systems — giving scientists clarity and decision makers confidence without adding operational overhead.

CMC is where drug development succeeds or fails — and it's been digitally underserved for too long. Over 70% of FDA rejection letters cite CMC deficiencies. Batch failures cost manufacturers millions per site, per year. And until now, there has been no purpose-built AI solution designed for the complexity of CMC in a regulated environment. Genedata Vico changes that. Vico is an AI-native software platform that gives CMC teams: ✔ Fully integrated CMC digital assets collection ✔ Purpose-built agentic AI to answer real CMC questions ✔ AI-enhanced process understanding and deviation detection ✔ Fully traceable, GxP-compliant analytics across your data ✔ Closed AI learning loops that improve with every new data point It's modality-agnostic, enterprise-ready, and proven in production — with Novartis using Genedata Vico to target an 80% reduction in preventable batch losses. CMC is too important to leave behind. Your teams deserve tools built for them.

Regulatory expectations for NGS assays are shifting. On May 7, biopharmaceutical experts share real-world strategies for bringing sequencing workflows into GMP environments — and staying compliant.

Join NGS industry experts at the virtual Genedata Selector Open Forum on May 7, 2026.

The Biopharma NGS Community is gathering on May 7 — Will you be there? Hear directly from the experts shaping NGS compliance and cell & gene therapy QC.